specific codon KRAS The mutations predict an overall survival (OS) benefit for patients with metastatic colorectal cancer (mCRC) treated with trifluridine-tipiracil (FTD/TPI; Lonsurf), based on a genomics-based analysis. After identifying resistance biomarkers and validating the findings in a real-world data set, the researchers demonstrated that patients with KRAS G12 mutant tumors in the phase III […]